COVID-19 severe or critically | |
COVID 19 outpatients | |
bamlanivimab/etesevimab | BLAZE-1 phase 2 ... BLAZE-1 phase 3 ... |
6528 | BLAZE-4, 0 | 1 | 1 | 0 | risk of bias not avaialble | ||
8968 | OPTIMISE-C19 (bamlanivimab-etesevimab vs casirivimab-imdevimab), 2021 | 1 | 1 | 3 | high risk of bias |